Answers are grounded in this paper and cite their sources.
Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
No takes yet. Share an insight, caveat, or question.
Selewski et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: